QoL Extended With Atezolizumab & #43; Bevacizumab in Liver Cancer
WEDNESDAY, Jan. 29, 2020 -- For patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab is associated with longer time to deterioration of patient-reported quality of life (QOL); and decline in...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Pharmaceuticals | Urology & Nephrology